-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Quisovalimab in Asthma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Quisovalimab in Asthma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Quisovalimab in Asthma Drug Details:AVTX-002 (AEVI-002, KHK-252067,SAR-252067) is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Quisovalimab in Crohn’s Disease (Regional Enteritis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Quisovalimab in Crohn's Disease (Regional Enteritis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Quisovalimab in Crohn's Disease (Regional Enteritis)Drug Details:AVTX-002 (AEVI-002, KHK-252067,SAR-252067) is under...
-
Company Profile
Aevis Victoria SA – Company Profile
Aevis Victoria SA (Aevis Victoria), a subsidiary of Medical Research, Services & Investments SA, is a diversified company that invests in healthcare, hospitality, telemedicine, life sciences, and lifestyle. It owns and operates outpatient surgical centers, hospitals, medical networks, and centers for the prevention of aging, radiology, and dental medicine. Aevis Victoria owns and manages various hotels in Switzerland. It also provides lease facilities to various hospitals under the Swiss Medical Network and supports over the long term. The company's hospitals...
Add to Basket -
Product Insights
Net Present Value Model: AVTX-007
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model AVTX-007 Drug Details AVTX-007 (AEVI-007) is...
-
Product Insights
Net Present Value Model: CERC-002
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model CERC-002 Drug Details AVTX-002 (AEVI-002, KHK-252067,SAR-252067)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AVTX-002
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry AVTX-002 Drug Details AVTX-002 (AEVI-002, KHK-252067,SAR-252067) is under development for the treatment of severe...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AVTX-007
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry AVTX-007 Drug Details AVTX-007 (AEVI-007) is under development for adult onset Still's disease (Rheumatoid...
-
Product Insights
Paralysis Global Clinical Trials Review, H1, 2018
GlobalData's clinical trial report, “Paralysis Global Clinical Trials Review, H1, 2018" provides an overview of Paralysis clinical trials scenario. This report provides top line data relating to the clinical trials on Paralysis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Attention Deficit Hyperactivity Disorder (ADHD) Global Clinical Trials Review, H1, 2017
GlobalData's clinical trial report, “Attention Deficit Hyperactivity Disorder (ADHD) Global Clinical Trials Review, H1, 2017" provides an overview of Attention Deficit Hyperactivity Disorder (ADHD) clinical trials scenario. This report provides top line data relating to the clinical trials on Attention Deficit Hyperactivity Disorder (ADHD). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
-
Sector Analysis
Competitor Landscape: Renal Anemia
Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the Renal Anemia market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher